bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2018: S A J J M A M F J
2017: D N O S

 
  Other news for:
Eye Diseases
Hereditary Diseases
 Resources from HONselect
Gene Therapy Approved for Rare Inherited Vision-Loss Disorders

By Scott Roberts

TUESDAY, Dec. 19, 2017 (HealthDay News) -- Luxturna, a form of gene therapy, has been approved to treat a rare group of inherited vision disorders that can lead to blindness.

The disorders are broadly grouped together and known as biallelic RPE65 mutation-associated retinal dystrophy. They affect a combined 1,000 to 2,000 people in the United States, the U.S. Food and Drug Administration said Tuesday in a news release.

Luxturna (voretigene neparvovec-rzyl) delivers a working copy of an existing defective gene that produces a retinal enzyme needed for normal vision.

"Today's approval marks another first in the field of gene therapy, both in how the therapy works and in expanding the use of gene therapy beyond the treatment of cancer to the treatment of vision loss," said FDA Commissioner Dr. Scott Gottlieb. "I believe gene therapy will become a mainstay for treating, and maybe curing, many of our most devastating and intractable illnesses."

Luxturna should be given only to people who have treatment-capable retinal cells, the agency said. Treatment must be done separately on each eye, at least six days apart.

The treatment was evaluated in clinical trials involving 41 people ranging in age from 4 to 44. The most common side effects included eye redness, cataracts, increased eye pressure and retinal tear.

Luxturna is produced by Spark Therapeutics, based in Philadelphia.

More information

The FDA has more about this approval.

SOURCE: Dec. 19, 2017 press release, U.S. Food and Drug Administration

Copyright © 2017 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=729537

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Gene Therapy
Therapeutics
Retinaldehyde
Eye
Affect
Lead
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact